In April 2008, iCureASPS started to support the research of Dr. Dina Lev, MD, on Alveolar Soft Part Sarcoma. Dr. Dina Lev is Assistant Professor at the Sarcoma Research Center, MD Anderson Cancer Center, Houston Texas. In November 2008, iCureASPS donated an additional $5,000 to her laboratory.
Dr. Lev published a study on angiogenesis-promoting genes in Alveolar Soft Part Sarcoma, in December 2007. Dr. Lev is also co-author in a study on the activation of the insulin growth factor receptor 1R (IGFR1) in ASPS, which was recently reported at the 2008 meeting of the American Association for Cancer Research (AACR).
Here is a summary of Dr. Lev’s research goals on Alveolar Soft Part Sarcoma:
The sarcoma research laboratory at MD Anderson Cancer Center is focused on the comprehensive multidisciplinary study of soft tissue sarcomas. One major area of interest is alveolar soft part sarcoma (ASPS). The rarity of these tumors and the lack of bioresources such as human tissues, cell lines, and animal models impedes intensive research in this field and thus enhanced molecular understanding as it relates to tumor inception and progression. Our major goals are to assemble and develop these needed bio-resources. Utilizing the MD Anderson Cancer Center tissue bank we were able to assemble an ASPS specific tissue microarray (TMA), which will potentially aid us in identifying the expression of genes and proteins of interest. ASPS are highly metastatic; their metastatic propensity is possibly secondary to their enhanced angiogenicity and vascularity. We have recently utilized the ASPS TMA to evaluate the expression of multiple angiogenic factors and other molecular targets; data stemming from these studies will hopefully be submitted for publication in recent months.
Our Research Aims:
1) To expand our annotated paraffin and frozen tissue bank for ASPS
2) To collaborate with other scientists with an interest in ASPS research
3) To study the expression and function of angiogenic factors in ASPS and evaluate their potential as therapeutic targets
4) To evaluate the effect of the TFE3 fusion gene on the expression of the studied angiogenic factors
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)